CoMentis is engaged in the discovery and development of new medicines to treat difficult neurovascular diseases. CoMentis’s development pipeline consists of: an oral α7 nAChR agonist in Phase II development for cognition enhancement; a non-invasive eyedrop therapy in Phase I development for age-related macular degeneration…